In this article, we will take a look at the 15 Best Stocks Under $25 to Buy Now.
Stock futures were marginally lower early December 29, as traders grabbed profits at record index levels and exited prominent technology names and precious metals following an explosive rally. The tech-heavy Nasdaq, blue-chip Dow Jones Industrial Average, and benchmark S&P 500 all finished down 0.5%, 0.5%, and 0.4%, respectively.
Meanwhile, gold and silver futures fell as exchange operator CME Group raised margin standards for the two metals together with platinum and palladium futures in light of recent market volatility. Silver also fell 8.7% in a single day, the worst decrease since February 2021. However, the next day, December 30, brought relief to the metals. Silver futures, which fell after reaching a high of $82.65 on December 29, recovered more than 8% to $76.25 per ounce.
Meanwhile, the Federal Reserve’s meeting minutes from December 30 revealed disagreements among FOMC members over their decision to lower interest rates earlier in the month. According to the minutes, inflation must fall before further declines can take place. Around 84% of bets are on the Fed maintaining current interest rate levels for the subsequent month, though traders are almost evenly split on what the committee will do in March.
That said, the S&P 500 is poised to end 2025 by about 18% in growth, marking the third consecutive year of double-digit percentage increases. For investors looking to the year beyond, Wharton’s Jeremy Siegel warned CNBC that the Magnificent Seven’s growth could decelerate, though this might result in more moderate increases for the S&P 500 overall.
Meanwhile, Peter Oppenheimer, chief global equities strategist at Goldman Sachs, adds that it would be unusual to witness an immense equity hiccup or bear market without a recession, especially with prospects of ongoing global growth along with further easing by the Fed.
Our Methodology
For this article, we made use of stock screeners to come up with an aggregated a list of stocks trading below $25, sorted by market capitalization. Next, we cross-checked the stock prices from Yahoo Finance and ranked the stocks in ascending order of the number of hedge fund holders sourced from Insider Monkey’s Q3 2025 database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
15. SailPoint, Inc. (NASDAQ:SAIL)
Share Price as of December 29: $20.98
Number of Hedge Fund Holders: 25
SailPoint, Inc. (NASDAQ:SAIL) ranks among the best stocks under $25 to buy now. In response to SailPoint, Inc. (NASDAQ:SAIL)’s latest quarterly reports, BMO Capital reaffirmed its Outperform rating and $25 price target on the company’s shares on December 11. Although the October quarter’s Annual Recurring Revenue (ARR) beat ended up less than that of the preceding two quarters, the firm indicated that SailPoint, Inc. (NASDAQ:SAIL) reported improvements across all measures.
The company’s SaaS ARR increased by 38% year-over-year to $669 million, accounting for 64% of overall ARR. Despite the solid overall performance, the quarter saw only a 1% increase in ARR. Moreover, the company recorded a net revenue retention (NRR) percentage of 114%, showing significant customer growth and retention.
BMO Capital presumes that management’s January quarter net new ARR guidance could boost the company’s shares in the near term. The firm added that SailPoint’s pipeline remains strong, owing to continuing conversions and new product cross-selling opportunities.
SailPoint, Inc. (NASDAQ:SAIL) provides enterprise identity security solutions by unifying identity data across employees, contractors, machines, and AI agents. The company’s products includes identity security cloud, atlas, connectivity and integrations, and identityIQ software platforms.
14. Venture Global, Inc. (NYSE:VG)
Share Price as of December 29: $7.02
Number of Hedge Fund Holders: 27
Venture Global, Inc. (NYSE:VG) ranks among the best stocks under $25 to buy now. Wells Fargo reduced its price target for Venture Global, Inc. (NYSE:VG) to $8 from $11 on December 15, maintaining an Equal Weight rating on the company’s shares. The firm identified operating expenses as a critical variable in its study, estimating cash operating expenses of $462 million in Q4 2025 and $2.0 billion in 2026.
Wells Fargo pointed out that these increases reflect Venture Global’s expanding asset base, which includes more vessels, trains, and customers, as well as labor prices and development costs associated with CP2 and the Plaquemines expansion.
Moreover, the company has been on a spree of partnerships, having signed a long-term LNG sales and purchase agreement (SPA) with Japan’s Mitsui & Co. last month. This follows two long-term LNG deals signed by the US player with European partners, one with Greece’s Atlantic-See LNG and the other with Spain’s Naturgy. In particular Atlantic-See LNG, a recently established joint venture between the Greek firms AKTOR and DEPA, agreed to purchase at least 0.5 mtpa of U.S. LNG from Venture Global, Inc. (NYSE:VG) for a period of 20 year beginning in 2030.
Venture Global, Inc. (NYSE:VG) is involved in the construction and development of liquefied natural gas production. The company’s projects include Calcasieu, Plaquemines, CP2, CP3, and Delta projects.
13. Summit Therapeutics Inc. (NASDAQ:SMMT)
Share Price as of December 29: $17.78
Number of Hedge Fund Holders: 27
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best stocks under $25 to buy now. Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on December 19, citing a strong outlook for the company. Summit’s upcoming global phase 3 HARMONi-3 study, which will evaluate ivonescimab plus chemotherapy in first-line non-small cell lung cancer (NSCLC), was noted as a critical milestone for 2026.
Summit Therapeutics Inc. (NASDAQ:SMMT) has stated that it would divide its HARMONi-3 trial into two histological cohorts, comparing ivonescimab with chemotherapy to pembrolizumab plus chemotherapy in the first-line regimen for metastatic squamous and non-squamous NSCLC.
The company intends to present preliminary findings for the HARMONi-3 squamous population in the latter half of 2026, with enrollment in the non-squamous cohort projected to conclude in the same period. Summit Therapeutics Inc. (NASDAQ:SMMT) estimates that the non-squamous cohort will pass the progression-free survival event threshold in the first half of 2027.
According to Cantor Fitzgerald, the study’s findings have the potential to be “biotech’s most important catalyst in 2026” and “the biggest binary event in the history of biotech.”
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company developing treatments for serious unmet medical needs, primarily in oncology, with its lead drug, ivonescimab, a bispecific antibody.
12. Stellantis N.V. (NYSE:STLA)
Share Price as of December 29: $9.42
Number of Hedge Fund Holders: 32
Stellantis N.V. (NYSE:STLA) ranks among the best stocks under $25 to buy now. On December 12, TD Cowen boosted Stellantis N.V. (NYSE:STLA)’s price target to $13 from $12, maintaining a Hold rating on the company’s shares. The firm expressed increasing confidence in the automaker’s North American recovery efforts, citing management’s enthusiasm for the vehicles, brand, and recovery mission as a major takeaway from recent talks.
The firm also stated that the HEMI mix might expand to 25-40% within 18-24 months, and that Cherokee volume is first aimed at retail, with the option for higher volume if import costs fall.
Stellantis N.V. (NYSE:STLA) also announced its plans of setting up Tesla’s North American Charging System for its electric vehicles in North America, Japan, and South Korea beginning in 2026. Stellantis N.V. (NYSE:STLA) is also slated to provide Uber with a minimum of 5,000 Level 4 autonomous vehicles to be used in a new robotaxi network. This collaboration entails employing NVIDIA’s DRIVE AGX Hyperion platform for autonomous vehicle operations.
Stellantis N.V. (NYSE:STLA) designs, engineers, manufactures, distributes, and sells cars, light commercial vehicles, engines, transmission systems, and mobility services worldwide. The company offers products under various brands, including Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS, Fiat, Fiat Professional, Jeep, Lancia, Opel, Peugeot, Ram, and Vauxhall.
11. Energy Transfer LP (NYSE:ET)
Share Price as of December 29: $16.27
Number of Hedge Fund Holders: 35
Energy Transfer LP (NYSE:ET) ranks among the best stocks under $25 to buy now. On December 15, RBC Capital reaffirmed coverage of Energy Transfer LP (NYSE:ET) with an Outperform rating and a $22 price target. The firm adjusted its model in response to the company’s recent earnings reports, the completion of SUN’s acquisition of Parkland, and USAC’s planned acquisition of J-W Power.
The company’s adjusted EBITDA reached $3.84 billion, compared to $3.96 billion in the previous year. Distributable cash flow was also recorded at $1.90 billion, a decrease from $1.99 billion the same period a year earlier. Energy Transfer LP (NYSE:ET) stated that the decreases were due to a number of one-time events, including an additional $43 million to settle a prior tax obligation.
RBC Capital feels that Energy Transfer LP (NYSE:ET) is well-positioned to benefit from rising natural gas demand, notably from data centers and LNG exports. However, the firm anticipates certain short-term headwinds in Energy Transfer’s NGL operations as key NGL pipeline contracts expire and must be renewed, possibly on additional conditions.
Energy Transfer LP (NYSE:ET) is a leading U.S. midstream energy company headquartered in Dallas, Texas. It operates over 140,000 miles of pipelines across 44 states, transporting and storing natural gas, crude oil, and natural gas liquids (NGLs).
10. Rivian Automotive, Inc. (NASDAQ:RIVN)
Share Price as of December 29: $20.67
Number of Hedge Fund Holders: 36
Rivian Automotive, Inc. (NASDAQ:RIVN) ranks among the best stocks under $25 to buy now. On December 12, Needham analyst Chris Pierce boosted Rivian Automotive, Inc. (NASDAQ:RIVN)’s price target to $23 from $14, retaining a Buy rating on the company’s shares. The boost comes after Rivian’s inaugural Autonomy & AI Day, where the company introduced its customized silicon chips, next-generation autonomy service, and extensive AI integration plan.
During the event, Rivian Automotive, Inc. (NASDAQ:RIVN) unveiled its third-generation Autonomy Compute Module (ACM3), which produces 1600 sparse INT8 TOPS (Trillion Operations Per Second), and its custom-built Rivian Autonomy Processor (RAP1). The company hopes to include this technology together with LiDAR into its planned R2 vehicles starting in late 2026.
Additionally, Rivian Automotive, Inc. (NASDAQ:RIVN) revealed plans to introduce Autonomy+, an autonomy subscription service, in early 2026. The service will cost $2,500 up front or $49.99 per month. The company also unveiled Rivian Assistant, an AI-powered next-generation speech interface that will be compatible with both first and second-generation R1 cars.
Rivian Automotive, Inc. (NASDAQ:RIVN) designs, develops, and manufactures category-defining electric vehicles and accessories. Its operations are divided into the following segments: Automotive, Software, and Services.
9. Vale S.A. (NYSE:VALE)
Share Price as of December 29: $12.92
Number of Hedge Fund Holders: 37
Vale S.A. (NYSE:VALE) ranks among the best stocks under $25 to buy now. On December 10, RBC Capital raised Vale S.A. (NYSE:VALE) from Sector Perform to Outperform, lifting its price target to $14.20 from $11. The increase comes after RBC increased its 2026-2029 iron ore price estimates by 13% due to a projected disruption in the Simandou project schedule, establishing Vale as a “clear winner” in the industry.
RBC predicts Vale’s dividend yield for fiscal year 2026 to be around 9%, more than doubling the 4% yield projected by the company’s rivals.
On December 2, Vale S.A. (NYSE:VALE) also stated that its subsidiary Vale Base Metals had inked an agreement with Glencore Canada to cooperatively evaluate a potential brownfield copper development project in their neighboring assets in the Sudbury Basin.
According to Vale S.A. (NYSE:VALE), the project involves the expanding of Glencore’s current mine shaft and the creation of new drifts to give access to surrounding copper deposits. Notably, the project is estimated to generate 880 kt of copper over 21 years.
Vale S.A. (NYSE:VALE) produces and exports copper, pellets, iron ore, manganese, and iron alloys. Its operations are divided into the Energy Transition Materials, Iron Solutions, and Coal and Others segments.
8. Wave Life Sciences Ltd. (NASDAQ:WVE)
Share Price as of December 29: $17.86
Number of Hedge Fund Holders: 38
Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best stocks under $25 to buy now. On December 16, Oppenheimer boosted its price target for Wave Life Sciences Ltd. (NASDAQ:WVE) to $32 from $24, maintaining an Outperform rating on the company’s shares. The firm reported “highly encouraging” interim results for WVE-007, emphasizing the treatment’s clean risk profile at doses up to 600mg and apparent ease of translation from human genetics and preclinical research to clinical outcomes.
According to Wave Life Sciences Ltd. (NASDAQ:WVE), the medication, when taken for three months, resulted in a 4.5% total fat loss, a 9.4% visceral fat reduction, and a 3.2% gain in lean mass. Wave Life Sciences Ltd (NASDAQ:WVE) stated it plans to release the results of the second round of the clinical trial, which will span six months for the 240 mg single-dose cohort and three months for the 400 mg single-dose cohort.
Beyond its immediate applications, Oppenheimer sees WVE-007 as a possible core therapy for not only obesity but also other cardiometabolic diseases.
Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotech company that develops and commercializes ribonucleic acid (RNA) medicines with the help of its proprietary PRISM discovery and drug development platform.
7. Remitly Global, Inc. (NASDAQ:RELY)
Share Price as of December 29: $14.05
Number of Hedge Fund Holders: 38
Remitly Global, Inc. (NASDAQ:RELY) ranks among the best stocks under $25 to buy now. On December 11, Citizens reaffirmed its Market Outperform rating and $20 price target on Remitly Global, Inc. (NASDAQ:RELY), noting the company’s leading role in the digital remittance industry. The firm believes Remitly Global, Inc. (NASDAQ:RELY) shares were overcorrected before the company’s Investor Day on account of immigration-related headlines, slowing revenue growth, and concerns regarding the introduction of small-dollar lending products.
Even with these hurdles, Citizens emphasizes Remitly’s position as the premier all-digital remittance vendor, with huge upside potential and plans to achieve industry-leading profitability in the long run.
During the Investor Day event, Remitly Global, Inc. (NASDAQ:RELY) announced its growth plans through 2028, with revenue expected to grow in the high teens and adjusted EBITDA between $300 million and $320 million by 2026. Remitly Global, Inc. (NASDAQ:RELY) also estimates revenue to range between $2.6 billion and $3.0 billion in 2028, with Adjusted EBITDA of $575 million to $600 million, representing a margin of 20-22%.
Remitly Global, Inc. (NASDAQ:RELY) is a financial technology and payments company that provides digital financial services with its cross-border payments app that facilitates money transfers in more than 170 countries around the world.
6. Genius Sports Limited (NYSE:GENI)
Share Price as of December 29: $10.98
Number of Hedge Fund Holders: 40
Genius Sports Limited (NYSE:GENI) ranks among the best stocks under $25 to buy now. On December 16, Citizens analyst firm maintained its Market Outperform rating for Genius Sports Limited (NYSE:GENI), with a $17 price target. The update comes amid legal worries in Arizona, where the state has banned prediction market offerings.
Citizens thinks Arizona’s measures against prediction markets might have a bearing on companies such as Fanatics, which has a gaming license as well as a high single-digit market share in Arizona, and PrizePicks, which runs on a fantasy license.
The firm notes that Genius Sports Limited (NYSE:GENI) provides data to traders who offer liquidity to firms getting cease-and-desist letters in Arizona, including Kalshi and Crypto.com, though it believes formal legal action against Genius Sports Limited (NYSE:GENI) is unlikely.
Moreover, on December 3, the company held its second Investor Day, during which it delivered a positive three-year outlook for revenue, adjusted EBITDA, and free cash flow, exceeding consensus estimates. Following this event, Guggenheim raised Genius Sports Limited (NYSE:GENI)’s’ price target to $17 while maintaining a Buy rating, while BTIG reiterated its $16 price target, citing advertising potential.
Genius Sports Limited (NYSE:GENI) develops and sells technology-led products and services to the sports, sports betting, and sports media industries.
5. American Airlines Group Inc. (NASDAQ:AAL)
Share Price as of December 25: $15.14
Number of Hedge Fund Holders: 43
American Airlines Group Inc. (NASDAQ:AAL) ranks among the best stocks under $25 to buy now. On December 18, Wells Fargo began coverage of American Airlines Group Inc. (NASDAQ:AAL), rating the stock Equal Weight and setting a price target of $17 on the company’s shares. The firm referenced American’s new co-branded card deal and improved main cabin economics as positive aspects, though it added that these advantages are outweighed by heightened debt levels and the demand for premium service upgrades.
Wells Fargo stated that American Airlines Group Inc. (NASDAQ:AAL) is poised to benefit significantly from its exclusive co-brand agreement with Citibank in 2026, with financial remuneration expected to increase by approximately 10% per year to $10 billion by 2030.
American Airlines Group Inc. (NASDAQ:AAL) is also exploring the use of Amazon.com Inc.’s Leo satellite-based internet service for in-flight Wi-Fi as part of a bid to attract premium customers and strengthen its competitive edge against rival US carriers. Amazon’s satellite network, formerly known as Project Kuiper, currently comprises around 150 satellites in orbit. The company intends to develop this to a system with over 3,200 units.
American Airlines Group Inc. (NASDAQ:AAL) is a major airline that provides passenger and cargo air transportation services. It operates an extensive network of domestic and international flights, serving over 350 destinations in more than 60 countries.
4. Roivant Sciences Ltd. (NASDAQ:ROIV)
Share Price as of December 29: $21.70
Number of Hedge Fund Holders: 54
Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now. Following the company’s analyst meeting on December 11, Leerink Partners boosted its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $32 from $29, keeping an Outperform rating on the company’s shares. The firm highlighted lower estimated operational expenses in the years ahead than previously modeled, resulting in reduced expected losses and significant profitability beginning in fiscal year 2029.
By the end of 2028, Roivant’s “Next 36 Month vision” anticipates at least three commercial launches, four or more NDA/BLA submissions, no less than eight crucial readouts, and at least three proof-of-concept evaluations.
Roivant Sciences Ltd. (NASDAQ:ROIV) has also advanced the development schedules for its primary therapeutic candidates, including brepocitinib, with a New Drug Application filing for dermatomyositis slated in early 2026 along with a possible commercial launch in early 2027. Furthermore, the Phase III trial for brepocitinib in non-infectious uveitis has reached full enrollment ahead of time, with topline results expected in the second half of 2026.
Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes medicines and technologies. Its clinical product candidates include IMVT-1402, an antibody that targets the neonatal Fc receptor for the treatment of Graves’ disease and difficult-to-treat rheumatoid arthritis.
3. Rocket Companies Inc. (NYSE:RKT)
Share Price as of December 29: $19.37
Number of Hedge Fund Holders: 77
Rocket Companies Inc. (NYSE:RKT) ranks among the best stocks under $25 to buy now. On December 19, Jefferies initiated coverage of Rocket Companies Inc. (NYSE:RKT), with a Buy rating and a $25 price target. The firm sees Rocket Companies Inc. (NYSE:RKT) as a vertically integrated system that will retain customers throughout the whole home purchase cycle, from browsing to signing and loan servicing.
Jefferies believes Rocket Companies Inc. (NYSE:RKT) shares may not yet represent the company’s increased earnings power, resilience, and competitive stance as a result of its acquisitions of Mr Cooper and Redfin, which concluded in the fourth and second quarters of 2025.
Mr. Cooper’s acquisition brought together America’s leading mortgage originator and the nation’s premier servicer. This merger produces a significant driving influence, with a combined service portfolio approaching 10 million clients and accounting for one in every six US mortgages.
Given Rocket’s structural advantages in data, scale, technology, and distribution, Jefferies anticipates that the company’s earnings per share in a normalized $2.5 trillion annual mortgage market will surpass current consensus projections.
Rocket Companies Inc. (NYSE:RKT) provides a range of mortgage, real estate, and personal finance services in the US and Canada. It operates through two segments: Direct to Consumer and Partner Network.
2. Pfizer Inc. (NYSE:PFE)
Share Price as of December 25: $25.00
Number of Hedge Fund Holders: 84
Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on December 17. The pharmaceutical company anticipates adjusted profit to be between $2.80 and $3 per share in the upcoming year. In comparison to the updated 2025 sales forecast of $62 billion, Pfizer’s revenue is anticipated to be essentially flat, coming between $59.5 billion and $62.5 billion.
Pfizer Inc. (NYSE:PFE) also forecasted a $1.5 billion year-over-year reduction in sales when certain medications lost market exclusivity. Some blockbuster treatments, such as the company’s pneumonia vaccination Prevnar, are seeing stronger rivalry from competitors.
BMO observed that Pfizer’s softer 2026 projection is mostly driven by prolonged uncertainty in its Covid business, which is expected to fall 23% year-over-year to around $5 billion in total revenue.
BMO anticipates that future talks will center on Pfizer’s recent purchase of Metsera and the company’s efforts to deliver ongoing cost savings, which have already exceeded their 2025 projections.
Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.
1. Nu Holdings Ltd. (NYSE:NU)
Share Price as of December 29: $16.66
Number of Hedge Fund Holders: 99
Nu Holdings Ltd. (NYSE:NU) ranks among the best stocks under $25 to buy now. On December 18, Goldman Sachs restated its Buy rating on Nu Holdings Ltd. (NYSE:NU) with a $21 price target, calling it one of its “best ideas” and stressing the digital bank’s solid growth prospects for the upcoming year. The firm anticipates Nu Holdings Ltd. (NYSE:NU) to have another stellar run, with analyst consensus forecasts already up 8% since the company’s Q3 2025 results.
Nu Holdings Ltd. (NYSE:NU) also added 4.3 million customers in the third quarter of 2025, bringing its total to 127 million, a 16% increase year-over-year and highlighting NU’s growing impact in Latin America’s financial sector. The average revenue per active customer (ARPAC) stood at a solid $13, up from $11 last year.
Despite some pressure from rising interest costs, Goldman Sachs believes Nu Holdings Ltd. (NYSE:NU) still has potential to raise its risk-adjusted net interest margins (NIMs). The firm points out that lower risk costs and increased credit ceilings, which will increase loan growth, should counteract this pressure.
Nu Holdings Ltd. (NYSE:NU) is a Brazil-based holding company that provides digital banking services. Its services include customized credit lines, mobile payments, interest-earning savings accounts, investment products, and more.
While we acknowledge the potential of NU to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NU and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
